Itacitinib + Corticosteroid
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Graft-versus-host Disease
Conditions
Acute Graft-versus-host Disease
Trial Timeline
Mar 20, 2018 → Feb 17, 2020
NCT ID
NCT03497273About Itacitinib + Corticosteroid
Itacitinib + Corticosteroid is a phase 1 stage product being developed by Incyte for Acute Graft-versus-host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03497273. Target conditions include Acute Graft-versus-host Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03497273 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Graft-versus-host Disease